摘要
目的观察卡培他滨治疗耐蒽环类药物晚期乳腺癌的近期疗效、不良反应及1年生存率。方法40例病理学检查证实的晚期乳腺癌,应用卡培他滨治疗共132周期,每例治疗2个周期后进行近期临床疗效和不良反应评定,21 d为1周期。结果40例总有效率32.5%(13/40),平均反应持续时间9.2个月。结论已经对蒽环类药物产生耐药的晚期乳腺癌患者,经卡培他滨治疗仍然有一定的疗效,不良反应可以耐受,可作为复发的晚期乳腺癌的二线治疗方案。
Objective To evaluate the response rate , adverse reactoin and survial rate of one year in the anthracycline-resistant relapsed breast cancer with capecitabine. Methods Forty relapsed breast cancer patients who had been proved by pathology had used capecitabine for 132 cycles,patients could be elevated after 2 cycles treatment,21 days was one cycle. Results The overall response rate of forty patients was 32.5% （13/40） ,median duration response was 9.2 months. Conclusions Capecitabine is effective for the relapsed paients who have been treated with anthracycline. The toxic effects are tolerante. Capecitabine can be used as the second line regimen for relapsed breast cancer.
出处
《肿瘤基础与临床》
2007年第5期397-398,共2页
journal of basic and clinical oncology
关键词
乳腺癌
化疗
投药和剂量
卡培他滨
breast cancer
drug therapy
administration ＆ dosage
capeticabine
